Glucokinase – Pipeline Review, H2 2020

Global Markets Direct’s, ‘Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) – Pipeline Review, H2 2020’, provides in depth analysis on Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Metabolic Disorders and Infectious Disease under development targeting Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)

– The report reviews Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC 2.7.1.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AstraZeneca Plc

Eli Lilly and Co

Hua Medicine Shanghai Ltd

Impetis Biosciences Ltd

Kriya Therapeutics Inc

Ligand Pharmaceuticals Inc

Merck & Co Inc

Pfizer Inc

Sanwa Kagaku Kenkyusho Co Ltd

vTv Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Overview

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Eli Lilly and Co

Hua Medicine Shanghai Ltd

Impetis Biosciences Ltd

Kriya Therapeutics Inc

Ligand Pharmaceuticals Inc

Merck & Co Inc

Pfizer Inc

Sanwa Kagaku Kenkyusho Co Ltd

vTv Therapeutics Inc

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Drug Profiles

AZD-1656 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dorzagliatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Glucokinase and Insulin for Diabetes and Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GKM-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KTA-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2608204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-04937319 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules 1 to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Glucokinase for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TTP-399 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Dormant Products

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Discontinued Products

Glucokinase (Hexokinase D or Hexokinase 4 or GCK or EC

2.7.1.2) - Product Development Milestones

Featured News & Press Releases

Oct 14, 2020: Hua Medicine announces the drug manufacturing permit granted for Dorzagliatin

Sep 16, 2020: vTv Therapeutics to present additional positive clinical study results from phase 2 Simplici-T1 study of TTP399 as adjunctive therapy for patients with type 1 diabetes at EASD Virtual Meeting

Jul 01, 2020: Hua Medicine announces positive 24-week topline results of phase III metformin combination trial of dorzagliatin

Jun 18, 2020: Hua Medicine successfully completes SEED (HMM0301), Dorzagliatin’s phase III Monotherapy trial

Jun 15, 2020: Hua Medicine’s Dorzagliatin demonstrates improvements in ß-Cell function in data presented at the American Diabetes Association’s 80th Scientific Sessions

Jun 13, 2020: vTv Therapeutics presents two late-breaking poster sessions on Simplici-T1 study at the American Diabetes Association’s Virtual Sessions supporting the potential of TTP399 as first-in-class oral adjunctive therapy for Type 1 Diabetes patients

May 31, 2020: Hua Medicine selected for inclusion in the MSCI Hong Kong Micro Cap Index

May 27, 2020: vTv Therapeutics to present full clinical study results from the positive phase 2 simplici-T1 study of TTP399, potential first-in-class oral adjunctive therapy for patients with type 1 diabetes at the American Diabetes Association’s 80th Virtual Scientific Sessions

Apr 27, 2020: Hua Medicine announces positive results of the combination study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor)

Feb 13, 2020: Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology Officer

Feb 10, 2020: vTv Therapeutics announces positive results from part 2 of the Phase 2 Simplici-T1 study of TTP399, potential first-in-class oral adjunctive therapy for patients with type 1 diabetes

Feb 07, 2020: vTv Therapeutics to host investor call and announce results from part 2 of the phase 2 Simplici-T1 Study of TTP399 - potential first-in-class oral adjunctive therapy for patients with Type 1 Diabetes

Jan 06, 2020: Hua Medicine announces positive results of HMM0110 and HMM0111

Nov 25, 2019: Hua Medicine’s global first-in-class drug was presented at 2019 Scientific Meeting of CDS

Nov 11, 2019: Hua Medicine’s pivotal phase III monotherapy trial of dorzagliatin, a dual-acting glucokinase modulator, achieves primary efficacy endpoint in patients with type 2 diabetes

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indication, H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by AstraZeneca Plc, H2 2020

Pipeline by Eli Lilly and Co, H2 2020

Pipeline by Hua Medicine Shanghai Ltd, H2 2020

Pipeline by Impetis Biosciences Ltd, H2 2020

Pipeline by Kriya Therapeutics Inc, H2 2020

Pipeline by Ligand Pharmaceuticals Inc, H2 2020

Pipeline by Merck & Co Inc, H2 2020

Pipeline by Pfizer Inc, H2 2020

Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2020

Pipeline by vTv Therapeutics Inc, H2 2020

Dormant Projects, H2 2020

Discontinued Products, H2 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Molecule Types, H2 2020

Number of Products by Stage and Molecule Types, H2 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports